SubsidieMeestersInnovative approach to an Individualised T-Cell Immunotherapy for cancer, using Personalised Tumour Trained Lymphocytes (pTTL) that is reliable, cost-effective, scalable and easy to implement
NEOGAP's project aims to develop a personalized T cell therapy for solid tumors using machine learning and neoantigen stimulation, with a focus on safety and biomarker exploration in colorectal cancer trials.
Projectdetails
Introduction
NEOGAP has developed a groundbreaking personalised adoptive T cell therapy for treating solid tumours based on two proprietary technologies: PIOR machine learning software and EpiTCer.
Therapy Overview
This cancer immunotherapy consists of producing personalised Tumour Trained Lymphocytes (pTTL), which are autologous T-cells harvested from regional lymph nodes. These T-cells are subjected to a neoantigen-driven T-cell stimulation technology to deliver highly tumour-reactive T-cell clones (pTTLs).
Mechanism of Action
pTTLs are re-infused to the patient where they infiltrate and kill cancer cells, leaving healthy cells untouched. The therapy is broadly applicable to many cancer types, being personalised to each individual patient.
Project Goals
In this EIC accelerator project, NEOGAP plans to:
- Complete a phase I/IIa clinical trial of the therapy in advanced colorectal cancer patients, focused on safety assessment and biomarker exploration.
- Optimise the manufacturing process for the next clinical studies.
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 2.500.000 |
| Totale projectbegroting | € 8.422.865 |
Tijdlijn
| Startdatum | 1-11-2023 |
| Einddatum | 31-1-2026 |
| Subsidiejaar | 2023 |
Partners & Locaties
Projectpartners
- NEOGAP THERAPEUTICS ABpenvoerder
Land(en)
Vergelijkbare projecten binnen EIC Accelerator
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Novel peptide-based therapeutics for reprogramming the tumour stroma extracellular matrix using molecular modelling and computational engineeringThe project aims to develop TAX2, a novel peptide therapy targeting the tumor microenvironment to inhibit solid tumor progression and enhance immunotherapy efficacy, with a focus on ovarian cancer. | EIC Accelerator | € 2.434.790 | 2025 | Details |
Novel peptide-based therapeutics for reprogramming the tumour stroma extracellular matrix using molecular modelling and computational engineering
The project aims to develop TAX2, a novel peptide therapy targeting the tumor microenvironment to inhibit solid tumor progression and enhance immunotherapy efficacy, with a focus on ovarian cancer.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Breakthrough Neoantigen-specific Tumor-Infiltrating Lymphocyte Therapies Through Novel Dendritic Cell ReprogrammingThe Repro-TIL project aims to enhance tumor-reactive TIL expansion for more effective immunotherapy in solid tumors, paving the way for improved treatment outcomes and commercialization. | EIC Transition | € 2.480.367 | 2025 | Details |
PRO CellecTPan Cancer T ontwikkelt een innovatieve TCR-gebaseerde therapie voor hard-to-treat kankers, met een strategisch plan om de commerciële haalbaarheid en waarde te maximaliseren. | Mkb-innovati... | € 20.000 | 2021 | Details |
Polyclonal anti-tumor immunity by engineered human T cellsThis project aims to enhance adoptive T cell therapies for solid tumors by engineering TCR sensitivity and safety, creating robust, antigen-agnostic immune responses to improve patient outcomes. | ERC Starting... | € 1.812.500 | 2022 | Details |
PREDICT - Towards a PREDICTable combination therapyHet project richt zich op het ontwikkelen van een datagestuurde combinatie van immuunsuppressie en NK-celtherapie om de uitkomst van kankerbehandelingen te voorspellen en te verbeteren. | Mkb-innovati... | € 165.355 | 2018 | Details |
Targeting Acute Leukemia with TdT-TCR-T-cell therapyThis project aims to commercialize a novel T-cell receptor therapy for acute lymphoblastic leukemia, demonstrating efficacy in pre-clinical models, with plans for a clinical trial and market analysis. | ERC Proof of... | € 150.000 | 2023 | Details |
Breakthrough Neoantigen-specific Tumor-Infiltrating Lymphocyte Therapies Through Novel Dendritic Cell Reprogramming
The Repro-TIL project aims to enhance tumor-reactive TIL expansion for more effective immunotherapy in solid tumors, paving the way for improved treatment outcomes and commercialization.
PRO CellecT
Pan Cancer T ontwikkelt een innovatieve TCR-gebaseerde therapie voor hard-to-treat kankers, met een strategisch plan om de commerciële haalbaarheid en waarde te maximaliseren.
Polyclonal anti-tumor immunity by engineered human T cells
This project aims to enhance adoptive T cell therapies for solid tumors by engineering TCR sensitivity and safety, creating robust, antigen-agnostic immune responses to improve patient outcomes.
PREDICT - Towards a PREDICTable combination therapy
Het project richt zich op het ontwikkelen van een datagestuurde combinatie van immuunsuppressie en NK-celtherapie om de uitkomst van kankerbehandelingen te voorspellen en te verbeteren.
Targeting Acute Leukemia with TdT-TCR-T-cell therapy
This project aims to commercialize a novel T-cell receptor therapy for acute lymphoblastic leukemia, demonstrating efficacy in pre-clinical models, with plans for a clinical trial and market analysis.